Philips launches Azurion worldwide, the next generation image-guided-therapy platform to enhance patient care and optimise lab productivity

 

  • Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of procedures, helping them to optimise interventional lab performance, provide superior care and reduce dose exposure
  • Azurion is powered by ConnectOS, Philips’ newly developed operating system to optimise system integration which features an intuitive user interface combined with real-time information on multiple work spots within the interventional lab

February 22, 2017

Guildford, United Kingdom – Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy (IGT) platform that integrates advanced interventional tools into one clinician platform. Combining advancements in vascular surgery, interventional cardiology, oncology and neuroradiology, Azurion provides procedure cards that  allow clinicians to pre-program routine tasks and user preferences while state-of-the-art ergonomic design and an intuitive user interface lets clinicians swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab.


Azurion is the result of a multi-year development program conducted in collaboration with leading clinicians in the field to acknowledge that with the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services.

 

Andy Rogers, Head of Radiation Physics Nottingham University Hospitals NHS Trust comments: “We are proud to partner with Philips UKI and to be one of the first centres in the world to receive this new advanced concept in IGT. We have found the pairing of excellent image quality with low radiation dose a great advantage when undertaking complex and lengthy cardiac procedures, while Azurion’s ease of use has let us quickly train staff on the system and integrate it into the cardiac catch lab environment. We are very excited with the future possibilities of integrating more of our equipment into a single touch-screen user interface, which will drive improvements in lab efficiency and superior patient care.”

 

Having acquired Volcano Corporation in 2015, subsequently becoming a leader in advanced catheters for diagnosis and therapy, Philips is further expanding its market footprint in the IGT market with one of its largest global product launches in recent years.

Azurion harnesses vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records to provide interventional staff members with the control and information they need for efficient procedures.

 

The Azurion platform features over 1,000 new components, including an enhanced flat-panel detector and Philips’ newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low radiation exposure and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously, saving valuable time without compromising quality of care.

 

“As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity,” said Bert van Meurs, Business Leader Image Guided Therapy at Philips. “Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs.”

Notes to editors:


About minimally invasive procedures:

 

Minimally-invasive therapies reduce patient trauma incidence, shorten recovery times allowing treatment to be offered to patients who would not be admissible for open surgery. Clinicians cannot directly see and feel the organs they are working on in minimally-invasive procedures so effective imaging, measurement and navigation technologies are key to guiding these procedures. At the heart of the interventional lab, imaging technologies allow identification and visualisation of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success.

For further information, please contact:

Sally Hilson

Philips Group Communications

Mob: +44 (0)7825 454 403    

E-mail: sally.hilson@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.